Health
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomized, double-blind, controlled, phase 3 trial – MD Linx
MDLinx original journal summary on Vaccines, Internal Medicine from The Lancet
Findings demonstrate the high efficacy of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG), in preventing laboratory-confirmed symptomatic COVID-19 disease in adults….
Continue Reading
-
Noosa News20 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
General22 hours agoEV buses join Perth’s wider suburban network, ‘milestone’ for diesel phase-out
-
Noosa News10 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News20 hours agoWoman loses arm in lion attack at Darling Downs Zoo in Queensland